Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Contrave, naltrexone SR/bupropion SR
print preview
bookmark
share with colleague
General Information
Company
Orexigen Therapeutics Inc.
Description
Fixed-dose combination of naltrexone HCL sustained release (SR) and bupropion HCL SR
Molecular Target
Mu opioid receptor (OPRM1) (MOR)
Mechanism of Action
Mu opioid receptor antagonist
Latest Stage of Development
Registration
Indication
Obesity
Partner
Takeda Pharmaceutical Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information